US 12,344,609 B2
WRN inhibitors
Derun Li, Boston, MA (US); Angela V. West, Franklin, MA (US); Justin Caravella, Cambridge, MA (US); Nathan E. Genung, Boston, MA (US); Florian Bartels, Berlin (DE); Robert Lee Dow, Groton, CT (US); Silvana Marcel Leit de Moradei, Burlington, MA (US); and Nikolay Sitnikov, Berlin (DE)
Assigned to Nimbus Wadjet, Inc., Boston, MA (US)
Filed by Nimbus Wadjet, Inc., Boston, MA (US)
Filed on Jan. 27, 2025, as Appl. No. 19/038,532.
Application 19/038,532 is a continuation of application No. 18/738,470, filed on Jun. 10, 2024.
Claims priority of provisional application 63/639,457, filed on Apr. 26, 2024.
Claims priority of provisional application 63/566,038, filed on Mar. 15, 2024.
Claims priority of provisional application 63/613,647, filed on Dec. 21, 2023.
Claims priority of provisional application 63/586,952, filed on Sep. 29, 2023.
Claims priority of provisional application 63/519,746, filed on Aug. 15, 2023.
Claims priority of provisional application 63/507,014, filed on Jun. 8, 2023.
Prior Publication US 2025/0171440 A1, May 29, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/4985 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/551 (2006.01); C07D 471/14 (2006.01); C07D 491/147 (2006.01); C07D 495/14 (2006.01); C07D 513/14 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); C07D 471/14 (2013.01); C07D 491/147 (2013.01); C07D 495/14 (2013.01); C07D 513/14 (2013.01); C07D 519/00 (2013.01)] 26 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.